Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 6/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.52 |
| ▸ | ATM | Q13315 | 2/20 | 0.52 |
| ▸ | XBP1 | P17861 | 1/20 | 0.52 |
| ▸ | PGR | P06401 | 1/20 | 0.52 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.52 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.52 |
| ▸ | HTR2A | P28223 | 1/20 | 0.52 |
| ▸ | HRH1 | P35367 | 1/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
| ▸ | CES2 | O00748 | 4/20 | 0.50 |
| ▸ | CES1 | P23141 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | DAO | P14920 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formaldehyde SCHEMBL10644284 | 0.81 | TDP1 (0.52) | L3MBTL1TDP1LMNASMN1; SMN2MAPT | |
| SCHEMBL13039632 | 0.80 | LMNA (0.56) | L3MBTL1TDP1LMNASMN1; SMN2MAPT | |
| SCHEMBL28283115 | 0.80 | TDP1 (0.56) | L3MBTL1TDP1LMNASMN1; SMN2MAPT | |
| SCHEMBL1397470 | 0.80 | KMT2A (0.58) | L3MBTL1TDP1LMNASMN1; SMN2MAPT | |
| SCHEMBL28960147 | 0.80 | TDP1 (0.56) | L3MBTL1TDP1LMNASMN1; SMN2MAPT | |
| SCHEMBL163939 | 0.80 | TDP1 (0.56) | L3MBTL1TDP1LMNASMN1; SMN2MAPT | |
| SCHEMBL6838801 | 0.79 | TDP1 (0.61) | L3MBTL1TDP1LMNASMN1; SMN2NPSR1 | |
| SCHEMBL8892267 | 0.79 | ALDH1A1 (0.52) | TDP1LMNASMN1; SMN2NPSR1ATM | |
| Bromide SCHEMBL8414921 | 0.78 | TDP1 (0.54) | L3MBTL1TDP1LMNASMN1; SMN2MAPT | |
| SCHEMBL1093883 | 0.78 | LMNA (0.58) | L3MBTL1TDP1LMNASMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1922310-A2 | TRIAZOLE DERIVATIVES USEFUL AS AXL INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2008-05-21 | — | — | EP | claimed |
| US-20070213375-A1 | Triazole derivatives useful as Axl inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2007-09-13 | — | — | US | claimed |
| WO-2007030680-A2 | TRIAZOLE DERIVATIVES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2007-03-15 | — | — | WO | claimed |
| US-8389557-B2 | Triazole derivatives useful as Axl inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20110082131-A1 | TRIAZOLE DERIVATIVES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2011-04-07 | — | — | US | disclosed |
| US-7884119-B2 | protein tyrosine kinase receptor inhibitors such as 3-amino -1-(1H-indol-5-yl)carbonyl-5-[4-2-(pyrrolidin-1-yl)ethoxy]phenylamino]-1H-1,2,4-triazole, used for treating diseases and conditions associated with neovascularization and/or cell proliferation | RIGEL PHARMACEUTICALS, INC. (US) | 2011-02-08 | — | — | US | disclosed |
| CN-100497345-C | 2, 3-dihydro-6-nitroimidazolo [2,1-b] oxazole compounds for the treatment of tuberculosis | OTSUKA PHARMA CO LTD (JP) | 2009-06-10 | — | — | CN | disclosed |
| EP-1678185-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2008-10-08 | — | — | EP | disclosed |
| CN-101248128-A | Coordination polymeric triethanolamine perchloric acid (triflato) metal inner complexes as additives for synthetic polymers | CATENA ADDITIVES GMBH & CO KG (DE) | 2008-08-20 | — | — | CN | disclosed |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | OTSUKA PHAMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| WO-2007030680-A2 | TRIAZOLE DERIVATIVES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2007-03-15 | — | — | WO | disclosed |
| CN-1878777-A | 2,3-dihydro-6-nitroimidazo (2,1-b) oxazole compounds for the treatment of tuberculosis | OTSUKA PHARMA CO LTD (JP) | 2006-12-13 | — | — | CN | disclosed |
| EP-1678185-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005042542-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | WO | disclosed |
| US-5691341-A | ANTILEUKEMIA AGENT | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-11-25 | — | — | US | disclosed |
| US-5639776-A | CROP PESTICIDE; NONPHYTOTOXIC, KIDNEY BEANS, ORANGES | OTSUKA KAGAKU KABUSHIKI KAISHA (JP) | 1997-06-17 | — | — | US | disclosed |
| EP-0751130-A1 | 4,5-DIHYDROPYRAZOLE-5-THIONE DERIVATIVES AND ACARICIDE CONTAINING THE SAME | OTSUKA KAGAKU KABUSHIKI KAISHA (JP) | 1997-01-02 | — | — | EP | disclosed |
| US-5464833-A | Anticarcinogenic agents, antiretrovirus agents or autoimmune diseases | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1995-11-07 | — | — | US | disclosed |
| EP-0623598-A1 | APOPTOSIS REGULATOR | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1994-11-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082131-A1 | TRIAZOLE DERIVATIVES USEFUL AS AXL INHIBITORS | AXL, TYRO3, FLT3 | L3MBTL1 1046/4885TDP1 993/4885LMNA 4114/4885 |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | NR2C2, NR0B2, NR4A2 | L3MBTL1 2575/4885TDP1 4548/4885LMNA 4594/4885 |
| US-20070213375-A1 | Triazole derivatives useful as Axl inhibitors | AXL, TYRO3, FLT3 | L3MBTL1 3170/4885TDP1 1945/4885LMNA 4227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.